Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining ...

Gilead Sciences ( ($GILD) ) has provided an update. On November 19, 2025, Gilead Sciences announced that Deborah H. Telman will step down from her ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 5 years ago, it would be worth $2,134.58 today based on a price of $128.61 for GILD at the time of writing.

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Deborah Telman is exiting months after the company paid $202 million to settle allegations that it provided illegal kickbacks ...

Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...

Recent analyst updates have led to a slight increase in Gilead Sciences’ fair value price target, moving from $127.23 to $129 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly ...

Around 1,000 doses of Gilead Sciences' HIV prevention drug, lenacapavir, were sent to Zambia and Eswatini under a U.S.

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...